Definitive Healthcare (NASDAQ:DH) Updates Q4 2024 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its fourth quarter 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.070-0.070 for the period, compared to the consensus estimate of 0.070. The company issued revenue guidance of $60.0 million-$61.0 million, compared to the consensus revenue estimate of $60.3 million. Definitive Healthcare also updated its FY 2024 guidance to 0.340-0.350 EPS.

Definitive Healthcare Trading Up 0.2 %

Definitive Healthcare stock traded up $0.01 during trading on Thursday, reaching $4.31. 543,720 shares of the company were exchanged, compared to its average volume of 748,693. The stock’s 50 day simple moving average is $4.38 and its two-hundred day simple moving average is $5.04. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.40 and a quick ratio of 2.40. The company has a market capitalization of $508.28 million, a P/E ratio of -1.24, a PEG ratio of 5.95 and a beta of 1.33. Definitive Healthcare has a 52-week low of $3.19 and a 52-week high of $10.62.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Monday, August 5th. The company reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. Definitive Healthcare had a negative net margin of 156.65% and a positive return on equity of 0.98%. The company had revenue of $63.70 million for the quarter, compared to the consensus estimate of $63.19 million. During the same period in the previous year, the firm earned $0.08 earnings per share. Definitive Healthcare’s quarterly revenue was up 4.4% compared to the same quarter last year. On average, equities research analysts expect that Definitive Healthcare will post 0.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DH has been the topic of a number of recent analyst reports. Morgan Stanley decreased their price objective on Definitive Healthcare from $9.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a research report on Tuesday, August 6th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Definitive Healthcare from $7.00 to $5.00 and set a “hold” rating on the stock in a report on Friday, August 9th. Stifel Nicolaus lowered their target price on shares of Definitive Healthcare from $9.50 to $7.50 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Finally, Robert W. Baird reduced their price target on shares of Definitive Healthcare from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $5.81.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.